SABS: Barclays Initiates Overweight
Barclays initiates coverage on SAB Biotherapeutics with an Overweight rating and a price target of $13
Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ: SABS ) with a Overweight rating and announces Price Target of $13.